Thus, TAMs’ HO-1 inhibition in the context of BC therapy could potentially lead to improved treatment outcomes by enhancing the effectiveness of chemotherapy and inhibiting tumor progression through HO-1-targeted reprogramming toward the M1 phenotype [192]. Here, HMOX1 is linked to neoplasm.